Xiuning Le, MD, PhD

Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.

Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.

Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Xiuning Le, MD, PhD, spoke about which patients with advanced non–small cell lung cancer with high MET-amplification could benefit most from tepotinib based on molecular markers.

Xiuning Le, MD, PhD, spoke about the use of ctDNA biomarkers and why research should continue for those with advanced non–small cell lung cancer with high MET-amplification being treated with tepotinib.

Xiuning Le, MD, PhD, spoke about unmet needs in patients with advanced non–small cell lung cancer with high MET-amplifications and why tepotinib may be a good treatment option.